曲美他嗪对慢性心力衰竭患者心功能以及血清基质金属蛋白酶-2的影响

Effects of trimetazidine on cardiac function and serum level of matrix metalloproteinase-2 in patients with chronic heart failure

目的探讨盐酸曲美他嗪对慢性心力衰竭(CHF)患者心功能和血清基质金属蛋白酶-2(MMP-2)的影响。方法将56例CHF患者随机分为治疗组(29例)和对照组(27例),两组均接受常规治疗(利尿剂、ACEI或洋地黄、β-受体阻滞剂),治疗组再加用盐酸曲美他嗪(20 mg口服,3次/d),治疗前及治疗后6个月均测心率、6 min步行距离、左室射血分数(LVEF)、基质金属蛋白酶-2(MMP-2)。结果疗程结束后,治疗组及对照组与治疗前相比,心率下降,血浆MMP-2浓度降低,LVEF升高(P<0.05);与对照组相比,治疗组LVEF升高更明显,血清MMP-2浓度更低(P<0.05)。血清MMP-2浓度与LVEF之间存在负相关(r=-0.65,P<0.01)。结论盐酸曲美他嗪能改善CHF患者的心功能,同时降低患者血清MMP-2的浓度。

Objective To investigate the effects of trimetazidine on cardiac function and serum level of matrix metalloproteinase-2 in patients with chronic heart failure（CHF）. Methods Fifty-six patients with CHF were randomly divided into two groups：treatment group（29 cases） and control group（27 cases）.All the patients were treated for 6 months besides conventional therapy including ACEI,β-receptor blocker,spironolactone or digoxin.Heart rates,serum MMP-2,and left ventricular ejection fraction（LVEF） were evaluated before and after therapy.Results Both treatment and control group significantly increased the LVEF,decreased the heart rates and serum MMP-2（P 0.05）,what＇s more,treatment group had much lower serum MMP-2 and higher LVEF than control group after 6 months of treatment（P〈0.05）,moreover the MMP-2 was negative correlated with LVEF.Conclusion Trimetazidine can improve cardiac function and decrease the serum MMP-2.